Literature DB >> 17173035

Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin.

Consuelo Garcia-Rodriguez1, Raphael Levy, Joseph W Arndt, Charles M Forsyth, Ali Razai, Jianlong Lou, Isin Geren, Raymond C Stevens, James D Marks.   

Abstract

Broadening antibody specificity without compromising affinity should facilitate detection and neutralization of toxin and viral subtypes. We used yeast display and a co-selection strategy to increase cross-reactivity of a single chain (sc) Fv antibody to botulinum neurotoxin type A (BoNT/A). Starting with a scFv that binds the BoNT/A1 subtype with high affinity (136 pM) and the BoNT/A2 subtype with low affinity (109 nM), we increased its affinity for BoNT/A2 1,250-fold, to 87 pM, while maintaining high-affinity binding to BoNT/A1 (115 pM). To find the molecular basis for improved cross-reactivity, we determined the X-ray co-crystal structures of wild-type and cross-reactive antibodies complexed to BoNT/A1 at resolutions up to 2.6 A, and measured the thermodynamic contribution of BoNT/A1 and A2 amino acids to wild-type and cross-reactive antibody binding. The results show how an antibody can be engineered to bind two different antigens despite structural differences in the antigen-antibody interface and may provide a general strategy for tuning antibody specificity and cross-reactivity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17173035     DOI: 10.1038/nbt1269

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  81 in total

1.  Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

Authors:  Cindi R Corbett; Erin Ballegeer; Kelly A Weedmark; M D Elias; Fetweh H Al-Saleem; Denise M Ancharski; Lance L Simpson; Jody D Berry
Journal:  Hybridoma (Larchmt)       Date:  2011-12

Review 2.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

3.  Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.

Authors:  Daniel M Held; Amy C Shurtleff; Scott Fields; Christopher Green; Julie Fong; Russell G A Jones; Dorothea Sesardic; Roland Buelow; Rae Lyn Burke
Journal:  Clin Vaccine Immunol       Date:  2010-04-21

4.  Preliminary X-ray crystallographic study of the receptor-binding domain of the D/C mosaic neurotoxin from Clostridium botulinum.

Authors:  Nipawan Nuemket; Yoshikazu Tanaka; Kentaro Tsukamoto; Takao Tsuji; Keiji Nakamura; Shunji Kozaki; Min Yao; Isao Tanaka
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-04-30

5.  Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.

Authors:  Qi Zhao; Mahiuddin Ahmed; Hong-fen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  J Biol Chem       Date:  2015-04-07       Impact factor: 5.157

6.  Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity.

Authors:  Qi Zhao; Yang Feng; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  Mol Cancer Ther       Date:  2011-07-12       Impact factor: 6.261

7.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

8.  RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin.

Authors:  Pavithra Janardhanan; Charlene M Mello; Bal Ram Singh; Jianlong Lou; James D Marks; Shuowei Cai
Journal:  Talanta       Date:  2013-09-13       Impact factor: 6.057

9.  Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.

Authors:  Jasmin Strotmeier; Stefan Mahrhold; Nadja Krez; Constantin Janzen; Jianlong Lou; James D Marks; Thomas Binz; Andreas Rummel
Journal:  FEBS Lett       Date:  2014-02-25       Impact factor: 4.124

Review 10.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.